Lexeo Therapeutics Inc
LXEO
NASDAQ
Biotechnology
$4.84
USD
-0.12 (-2.42%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $363.56M
Volume 676.6K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-87.27M
TTM
+23.6%
YoY
Operating Cash Flow
$-88.37M
TTM
+7.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 16.0 | 6.0 | 6.9 | 6.6 | 9.0 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 30.7 | 21.6 | 23.1 | 22.3 | 28.0 |
Operating Income | -30.7 | -21.6 | -23.1 | -22.3 | -28.0 |
EBITDA | -30.6 | -21.7 | -23.0 | -22.3 | -27.9 |
Other Income / Expense | 3.4 | -0.1 | 0.1 | 0.0 | -0.0 |
Total Other Income / Expense | 4.6 | 1.4 | 2.2 | 2.1 | 2.2 |
Income Before Income Taxes | -26.1 | -20.3 | -20.9 | -20.2 | -25.9 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -26.1 | -20.3 | -20.9 | -20.2 | -25.9 |
Consolidated Net Income / Loss | -26.1 | -20.3 | -20.9 | -20.2 | -25.9 |
Net Income Attributable to Common Shareholders | -26.1 | -20.3 | -20.9 | -20.2 | -25.9 |
Basic EPS | -$0.60 | -$0.33 | -$0.27 | -$0.25 | -$0.30 |
Diluted EPS | -$0.60 | -$0.33 | -$0.27 | -$0.25 | -$0.30 |
Basic Shares Outstanding | 43.6M | 61.0M | 76.9M | 81.2M | 85.6M |
Diluted Shares Outstanding | 43.6M | 61.0M | 76.9M | 81.2M | 85.6M |